US FDA halts Sun Pharma's trials on dermatological drug
The company said it would work closely with the US FDA to address the agency's concerns, which the drugmaker expected to be communicated within the next 30 days
The company said it would work closely with the US FDA to address the agency's concerns, which the drugmaker expected to be communicated within the next 30 days